The rapid weight loss achieved through GLP-1 medications like Ozempic and Wegovy has captured public attention, offering a potentially powerful tool in the fight against obesity. Though, a growing body of research indicates that maintaining that loss after discontinuing the drugs can be a significant challenge, with many individuals experiencing weight regain. Whereas stopping these medications often leads to a rebound, emerging data suggests that a substantial minority – around 25% – may be able to sustain a meaningful portion of their weight loss.
Obesity rates in the United States have been steadily climbing, but recent surveys indicate a possible shift. According to a Gallup National Health and Well-Being Index survey, the obesity rate dropped to 37% of U.S. Adults in 2025, down from a high of 39.9% three years prior. This decline coincides with increased use of injectable obesity treatments, with 12.4% of respondents reporting taking drugs like semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro) for weight loss, compared to 5.8% in February 2024. These medications, known as GLP-1 agonists, were first approved for obesity treatment in the U.S. In 2021 and work by influencing brain activity and hormone regulation to suppress hunger and slow digestion.
The Challenge of Weight Regain
The concern about weight regain isn’t fresh. A study highlighted by The New York Times found that approximately half of patients stop taking GLP-1s within a year, often due to the cost and side effects. However, even among those who continue, the long-term sustainability of weight loss remains a key question. Public health experts emphasize that “obesity is a chronic relapsing condition that cannot be cured with a drug alone,” underscoring the need for comprehensive lifestyle interventions.
The experience of regaining weight after stopping GLP-1s is echoed in personal accounts. A recent New York Post article featured individuals who described these medications as “not a magic pill, it’s a life preserver,” highlighting their temporary nature and the necessity of adopting long-term healthy habits. The financial burden of these drugs also contributes to discontinuation, as noted in a recent New York Times opinion piece where participants discussed the challenges of affording both the medication and a healthy diet. One participant stated, “Trying to balance everything else out financially to eat good, you have to be able to afford it. And I think a lot of people can’t.”
Strategies for Sustaining Weight Loss
Despite the challenges, research suggests that some individuals can maintain a significant portion of their weight loss after stopping GLP-1s. A recent study, as reported by The New York Times, found that patients receiving injections less frequently were still able to maintain weight loss and health benefits. This suggests that a tailored approach to dosage and discontinuation may be crucial. Experts recommend a gradual tapering of the medication, combined with intensive lifestyle modifications, including dietary changes and increased physical activity.
The BBC Science Focus Magazine offers guidance on the best way to approach off weight-loss drugs without regaining fat, emphasizing the importance of a structured plan developed in consultation with a healthcare professional. This plan should focus on establishing sustainable eating patterns and incorporating regular exercise into daily life. Addressing underlying behavioral and psychological factors that contribute to weight gain is essential for long-term success.
Regional Trends and Future Outlook
The impact of GLP-1 drugs isn’t uniform across the country. Minnesota, for example, has seen declining obesity rates alongside increased GLP-1 use, according to the Star Tribune. This suggests that access to and utilization of these medications may be contributing to positive public health outcomes in certain regions.
As more data emerges, a clearer picture of the long-term effects of GLP-1s will develop. Ongoing research is focused on identifying factors that predict successful weight loss maintenance and developing strategies to mitigate regain. The focus is shifting towards viewing these medications as part of a broader, holistic approach to obesity management, rather than a standalone solution. The next steps involve refining treatment protocols and expanding access to comprehensive support services to help individuals sustain their weight loss journey.
This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the role of medication in managing obesity? Share your comments below, and please share this article with anyone who might find it helpful.
